HOME > COMMENTARY
COMMENTARY
-
How Will Simplified Delisting, Elective Care Affect G1 Withdrawal Scheme?
August 7, 2024
-
Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
August 6, 2024
-
Lively Debate on Generic Industry Revamp Underway, All Eyes on Consortium Model
July 12, 2024
-
Industry’s Ability to Communicate Being Put to Test as Views on Off-Year Price Cuts Change
June 11, 2024
-
With Only 5 Months Until Nitrosamine Self-Inspection Deadline, Many Challenges Remain
June 7, 2024
-
Japan Employees Shaken by Teva’s Divestment Plan, Soft Landing Wanted on Supply Front
June 4, 2024
-
Can Japan Generic Industry Accelerate Self-Reform? MHLW Panel Debate Now in Homestretch
April 19, 2024
-
With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
-
With So Many of Its Demands Met, How Will Industry Oppose Off-Year Price Revisions in FY2025?
March 12, 2024
-
Is Case of Leqembi a “Steppingstone” to New CEA Price Adjustment Rule? Pharma Industry on Guard
January 30, 2024
-
Goals of the “Innovation Box” Tax Break in FY2024 Reform
January 23, 2024
-
Introduction of Elective Care to Mark Watershed for Long-Listed Drug Makers
January 17, 2024
-
Change of Tide in Reform: Lopsided Cost Cuts to Balanced Pro-Innovation Policy
December 27, 2023
-
Key Figures in Next Drug Pricing Reform Now All in Place, In What Direction Will They Go for Pro-Innovation Drive?
November 15, 2023
-
Predicting Clinical, Financial Impact of Hemophilia Gene Therapy in Japan
November 7, 2023
-
Reform Proposal Signals Perception Gap between Industry, Govt on Purpose of Market Expansion Re-Pricing
October 31, 2023
-
With 2nd Strategy Penned, Can Japan Play Catch-Up with US & Europe in SaMD Push?
October 3, 2023
-
Hopes to Nix Budget Ceiling Dashed, How Will Industry Get Its Message Across to Govt?
September 4, 2023
-
Chuikyo Embracing Industry Opinions in Early Phase of Drug Pricing Debate
August 29, 2023
-
Can “G1” Withdrawal Scheme Be Improved Enough to Serve Its Purpose?
August 23, 2023
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
